Lv1
38 积分 2024-06-27 加入
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer
4天前
已完结
Multi-omics analyses reveal the pathogenic role of terminal ileum-derived IgA+β7+ cells in IgA nephropathy
6天前
已完结
Implication of decreased serum complement 3 in patients with diabetic nephropathy
10天前
已完结
Immunoglobulin A Nephropathy: Molecular Pathogenesis and Targeted Therapy
3个月前
已完结
Lipid metabolism drives dietary effects on T cell ferroptosis and immunity
5个月前
已完结
[Multidisciplinary consensus on the diagnosis and treatment of atypical hemolytic uremic syndrome (2025 version)]
6个月前
已完结
Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy
6个月前
已完结
Innate immune and metabolic signals induce mitochondria-dependent membrane lysis via mitoxyperiosis
6个月前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
6个月前
已完结
TRPC6 inhibition for the treatment of focal segmental glomerulosclerosis: a randomised, placebo-controlled, phase 2 trial of BI 764198
6个月前
已完结
皖公网安备34019202002308
